Benchmark for Setting ACTH Cell Dosage in Clinical Regenerative Medicine for Post-Operative Hypopituitarism.

ABSTRACT:

Background/objectives

Our objective is to develop hormone-producing pituitary cells that can function in the same manner as the human body and provide more effective treatments than current hormone replacement therapy. We have already established a technique for generating hypothalamic-pituitary organoids using feeder-free human pluripotent stem cells (hPSCs) and demonstrated their effectiveness in vivo through transplantation into hypopituitary mouse models. To prospectively determine the upper limit of transplanting adenohypophyseal cells into humans, we investigated the human maximum secretion capacity of adrenocorticotropic hormone (ACTH) and growth hormone (GH).

Methods

We analyzed data from 28 patients with pituitary adenomas, among whom 16 evinced no abnormality of AC

SUBMITTER: Kondo T 

PROVIDER: S-EPMC12025586 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature